Australian biotech market watch 22/07/09
Wednesday, 22 July, 2009
The All Ordinaries has bounced up this week, pipping the 4,000 mark for the first time since mid-June, buoyed by optimistic mumblings from the US and Chinese markets along with indications the Australian market has touched bottom and is on its way up for a breath.
The health indices followed a similar pattern to the All Ords, at least until this morning, when they shed much of the gains made earlier in the week, dropping 59 points to 7,757.
After a turbulent couple of weeks, Cochlear (ASX:COH) gained ground through Monday and Tuesday, only to slip 1.3% in today's trading to $54.10.
Fisher & Paykel Healthcare (ASX:FPH) has continued to make gains, pushing its recent two month high to $2.48.
After it was announced that the competition watchdog is considering launching an investigation into pathology billing practices, both Primary Health Care (ASX:PRY) and Sonic Health Care (ASX:SHL) are down, by 3.4% and 3% respectively. This comes hot on the heels of Primary Health Care issuing 10 million new shares on Monday.
Ramsay Health Care (ASX:RHC), which had a strong week last week, shed 24c in today's trading to hit $10.61.
ResMed dropped sharply on Tuesday morning but has clawed its way back to close to Monday's close, sitting at $4.92 around 2.30pm, up 1.44% for the day.
Sigma Pharmaceuticals (ASX:SIP) has made steady gains since Monday morning, up 4.9% today to $1.29.
Ansell and CSL remain steady.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
